Highlights of ASH in CLL
John Gribben et al.
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Overview of Bruton's tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia
The characteristics and mode of action of ibrutinib for CLL